GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT
Published: Dec 21, 2020 BEVERLY HILLS, Calif, Dec. 21, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Companys proprietary NK cell engager (TriKE™) technology platform is pleased to announce the presentation of additional interim data results for the Companys lead therapeutic candidate, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Invest...
United States Anthony Cataldo Erica Warlick Beverly Hills Exchange Commission American Society Of Hematology
Source: biospace.com